Renhe Pharmacy Co., Ltd.

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE000000NF8
CNY
5.71
0.02 (0.35%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationQuarterly Results
Results Snapshot
YoYQoQ
Figures in Million
Consolidate Quarterly Results
Mar'26
Dec'25
Sep'25
Jun'25
Mar'25
Dec'24
Sep'24
Net Sales
1,129.22
702.97
858.36
989.45
978.03
924.26
786.30
Other Operating Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Total Operating income
1,129.22
702.97
858.36
989.45
978.03
924.26
786.30
Raw Material Cost
714.76
447.69
568.79
643.33
635.87
581.39
524.09
Purchase of Finished goods
0.00
0.00
0.00
0.00
0.00
0.00
0.00
(Increase) / Decrease In Stocks
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Employee Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Power Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
0.02
0.02
0.02
0.02
0.02
0.07
0.02
Selling and Distribution Expenses
161.19
123.24
145.54
134.64
166.51
179.03
139.53
Other Expenses
0.74
1.80
0.51
1.19
0.75
1.98
0.49
Total Expenditure (Excl Depreciation)
883.40
588.92
719.43
789.86
809.89
780.32
668.55
Operating Profit (PBDIT) excl Other Income
245.79999999999998
114
138.9
199.60000000000002
168.1
143.9
117.8
Other Income
10.78
50.17
26.80
24.14
81.18
58.62
34.82
Operating Profit (PBDIT)
246.48
53.31
186.70
243.14
278.97
110.29
176.93
Interest
0.02
0.02
0.02
0.02
0.02
0.07
0.02
Exceptional Items
-2.43
25.94
-0.87
0.06
-0.02
16.75
0.23
Gross Profit (PBDT)
414.47
255.28
289.57
346.12
342.17
342.87
262.22
Depreciation
0.00
29.75
29.75
29.59
29.59
34.18
34.18
Profit Before Tax
244.04
49.47
156.07
213.58
249.34
92.80
142.97
Tax
64.68
30.30
41.03
54.27
51.64
39.57
39.47
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Profit After Tax
140.37
14.07
88.71
126.12
164.31
66.23
78.50
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Net Profit
140.37
14.07
88.71
126.12
164.31
66.23
78.50
Share in Profit of Associates
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Minority Interest
37.86
4.47
25.16
32.39
32.43
-14.55
23.69
Other related items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
178.23
18.55
113.87
158.51
196.74
51.68
102.20
Equity Capital
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Face Value
1.0
1.0
1.0
1.0
1.0
1.0
1.0
Reserves
6,455.93
6,315.57
6,351.81
6,264.55
6,342.03
6,173.66
6,097.67
Earnings per share (EPS)
0.1
0.01
0.06
0.09
0.12
0.05
0.06
Diluted Earnings per share
0.1
0.01
0.06
0.09
0.12
0.05
0.06
Operating Profit Margin (Excl OI)
20.87%
-3.79%
15.16%
19.14%
17.2%
1.89%
13.73%
Gross Profit Margin
21.61%
11.27%
21.65%
24.58%
28.52%
13.74%
22.53%
PAT Margin
12.43%
2.0%
10.33%
12.75%
16.8%
7.17%
9.98%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Quarterly Analysis Highlights - QoQ
stock-summary

Net Sales

QoQ Growth in quarter ended Mar 2026 is 60.63% vs -18.10% in Dec 2025

stock-summary

Consolidate Net Profit

QoQ Growth in quarter ended Mar 2026 is 863.24% vs -83.76% in Dec 2025

stock-summary

Operating Profit (PBDIT) excl Other Income

QoQ Growth in quarter ended Mar 2026 is 7,503.23% vs -98.06% in Dec 2025

stock-summary

Interest

No Interest in the last few periods

stock-summary

Operating Profit Margin (Excl OI)

QoQ Growth in quarter ended Mar 2026 has improved from Dec 2025

Compare Quarterly Results Of Renhe Pharmacy Co., Ltd. With
Markets Mojo
Figures in Million
Consolidate Quarterly Results
Markets Mojo
Markets Mojo
Change(CNY)
Change(%)
Net Sales
1,129.22
0
1,129.22
Other Operating Income
0.00
0.00
0.00
Total Operating income
1,129.22
0
1,129.22
Raw Material Cost
714.76
0
714.76
Purchase of Finished goods
0
0
0.00
(Increase) / Decrease In Stocks
0
0
0.00
Employee Cost
0.00
0
0.00
Power Cost
0
0
0.00
Manufacturing Expenses
0.02
0
0.02
Selling and Distribution Expenses
161.19
0
161.19
Other Expenses
0.74
0.00
0.74
Total Expenditure (Excl Depreciation)
883.40
0
883.40
Operating Profit (PBDIT) excl Other Income
245.82
0.00
245.82
Other Income
10.78
0
10.78
Operating Profit (PBDIT)
246.48
0
246.48
Interest
0.02
0
0.02
Exceptional Items
-2.43
0
-2.43
Gross Profit (PBDT)
414.47
0
414.47
Depreciation
0.00
0
0.00
Profit Before Tax
244.04
0
244.04
Tax
64.68
0
64.68
Provisions and contingencies
0
0
0.00
Profit After Tax
140.37
0
140.37
Extraordinary Items
0.00
0
0.00
Prior Period Expenses
0
0
0.00
Other Adjustments
0
0
0.00
Net Profit
140.37
0
140.37
Share in Profit of Associates
0
0
0.00
Minority Interest
37.86
0
37.86
Other related items
0.00
0.00
0.00
Consolidated Net Profit
178.23
0
178.23
Equity Capital
0
0
0.00
Face Value
1.00
0
0.00
Reserves
6,455.93
0
6,455.93
Earnings per share (EPS)
0.10
0
0.10
Diluted Earnings per share
0.10
0
0.10
Operating Profit Margin (Excl OI)
20.87%
0%
0.00
20.87%
Gross Profit Margin
21.61%
0%
0.00
21.61%
PAT Margin
12.43%
0%
0.00
12.43%
Public Share Holdings (%)
0%
0%
0.00
0.00%
Pledged Promotor Holding (%)
0%
0%
0.00
0.00%
Quarterly - Net Sales
Net Sales 112.92 Million
in Mar 2026

Figures in Million
stock-summary

QoQ Growth in quarter ended Mar 2026 is 60.63% vs -18.10% in Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 is 15.46% vs -20.98% in Mar 2025

Quarterly - Consolidate Net Profit
Consolidate Net Profit 17.82 Million
in Mar 2026

Figures in Million
stock-summary

QoQ Growth in quarter ended Mar 2026 is 863.24% vs -83.76% in Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 is -9.41% vs -6.24% in Mar 2025

Quarterly - Operating Profit (PBDIT)
Operating Profit (PBDIT) 23.57 Million
in Mar 2026

Figures in Million
stock-summary

QoQ Growth in quarter ended Mar 2026 is 7,503.23% vs -98.06% in Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 is 19.16% vs -2.27% in Mar 2025

Quarterly - Interest
Markets Mojo
No Interest in the last few periods
Quarterly - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 20.87%
in Mar 2026

Figures in %
stock-summary

QoQ Growth in quarter ended Mar 2026 has improved from Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 has improved from Mar 2025